| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | President, Research & Development | Stock Option (right to buy) | 140,890 | 19 Jan 2022 | Direct | ||
| Climb Bio, Inc. | Director | Stock Option (Right to Buy) | 40,000 | 04 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CLYM | Climb Bio, Inc. | 04 Jun 2025 | 1 | $0 | 4 | Director | 05 Jun 2025, 16:11 |
| CLYM | Eliem Therapeutics, Inc. | 26 Jun 2024 | 1 | $0 | 4 | Director | 28 Jun 2024, 17:23 |
| CLYM | Eliem Therapeutics, Inc. | 18 May 2023 | 1 | $0 | 4 | Director | 22 May 2023, 17:08 |
| CLYM | Eliem Therapeutics, Inc. | 19 May 2022 | 1 | $0 | 4 | Director | 01 Jun 2022, 17:02 |
| FULC | Fulcrum Therapeutics, Inc. | 19 Jan 2022 | 1 | $0 | 4 | President, Research & Development | 21 Jan 2022, 15:15 |
| CLYM | Eliem Therapeutics, Inc. | 09 Aug 2021 | 0 | $0 | 3 | Director | 09 Aug 2021, 18:27 |